ResMed (NYSE: RMD ) is expected to report Q2 earnings on Jan. 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ResMed's revenues will grow 8.7% and EPS will grow 15.9%.
The average estimate for revenue is $361.6 million. On the bottom line, the average EPS estimate is $0.51.
Last quarter, ResMed booked revenue of $339.7 million. GAAP reported sales were 7.9% higher than the prior-year quarter's $314.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.50. GAAP EPS of $0.49 for Q1 were 48% higher than the prior-year quarter's $0.33 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 61.4%, 260 basis points better than the prior-year quarter. Operating margin was 23.7%, 440 basis points better than the prior-year quarter. Net margin was 21.0%, 500 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $1.50 billion. The average EPS estimate is $2.18.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 187 members out of 202 rating the stock outperform, and 15 members rating it underperform. Among 66 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 64 give ResMed a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ResMed is hold, with an average price target of $36.83.
Is ResMed the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add ResMed to My Watchlist.